Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07176351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

StatusNot Yet Recruiting
PhasePhase 4
Started2026-08
View on ClinicalTrials.gov ↗

Amendment history

2026-07-29
Study Status v3
Start date2026-04→2026-08
2026-04-01
Study Status, Sponsor/Collaborators v2
Start date2026-03→2026-04
Collaborators1 entry, revised
Braeburn IncPharmaceuticals
2026-02-02
Study Status, Oversight v1
Start date2025-12→2026-03
2025-09-08
Original filing
Yale University
487 trials monitored
See 35 trials at risk
This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC). Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.
Trial Details
NCT Number NCT07176351
Lead Sponsor Yale University
Collaborators: Braeburn Pharmaceuticals
Conditions Opioid Use Disorder
Enrollment 60 participants
Start Date 2026-08
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-31